NZ598000A - Composition for treating hbv infection - Google Patents

Composition for treating hbv infection

Info

Publication number
NZ598000A
NZ598000A NZ598000A NZ59800010A NZ598000A NZ 598000 A NZ598000 A NZ 598000A NZ 598000 A NZ598000 A NZ 598000A NZ 59800010 A NZ59800010 A NZ 59800010A NZ 598000 A NZ598000 A NZ 598000A
Authority
NZ
New Zealand
Prior art keywords
combination
polymerase
amino acid
moiety
hbv virus
Prior art date
Application number
NZ598000A
Other languages
English (en)
Inventor
Perrine Martin
Genevieve Inchauspe
Nathalie Silvestre
Doris Schmitt
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of NZ598000A publication Critical patent/NZ598000A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ598000A 2009-08-07 2010-08-06 Composition for treating hbv infection NZ598000A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305742 2009-08-07
PCT/EP2010/061492 WO2011015656A2 (en) 2009-08-07 2010-08-06 Composition for treating hbv infection

Publications (1)

Publication Number Publication Date
NZ598000A true NZ598000A (en) 2013-10-25

Family

ID=43087099

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598000A NZ598000A (en) 2009-08-07 2010-08-06 Composition for treating hbv infection

Country Status (15)

Country Link
US (2) US9393299B2 (enExample)
EP (1) EP2461826A2 (enExample)
JP (2) JP5897464B2 (enExample)
KR (1) KR20120052352A (enExample)
CN (2) CN105535960B (enExample)
BR (1) BR112012002628B1 (enExample)
CA (1) CA2770075C (enExample)
IL (1) IL217926A (enExample)
MX (1) MX2012001592A (enExample)
NZ (1) NZ598000A (enExample)
RU (1) RU2555346C2 (enExample)
SG (1) SG178254A1 (enExample)
TW (1) TWI555531B (enExample)
WO (1) WO2011015656A2 (enExample)
ZA (1) ZA201200899B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770075C (en) * 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
WO2012174220A1 (en) 2011-06-14 2012-12-20 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US9946495B2 (en) * 2013-04-25 2018-04-17 Microsoft Technology Licensing, Llc Dirty data management for hybrid drives
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
MX2017011732A (es) 2015-03-18 2018-08-15 Omnicyte Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
CN106148404B (zh) * 2015-03-25 2020-01-24 复旦大学 一种人乙型肝炎病毒重组载体及其应用
JP6566368B2 (ja) * 2015-04-16 2019-08-28 国立研究開発法人産業技術総合研究所 Ｂ型肝炎ウイルス分泌阻害剤
EP4177348A1 (en) * 2015-11-04 2023-05-10 Hookipa Biotech GmbH Vaccines against hepatitis b virus
ES2922981T3 (es) 2015-11-12 2022-09-22 Hookipa Biotech Gmbh Partículas de arenavirus como vacunas contra el cáncer
US9963751B2 (en) 2015-11-24 2018-05-08 The Penn State Research Foundation Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA
CA3002508A1 (en) * 2016-01-12 2017-07-20 Ulrike Protzer Means and methods for treating hbv
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
US11052148B2 (en) 2016-05-30 2021-07-06 Geo Vax, Inc. Compositions and methods for generating an immune response to hepatitis B virus
KR20190020745A (ko) * 2016-06-15 2019-03-04 옥스포드 유니버시티 이노베이션 리미티드 Abc4a를 발현시키기 위한 이중 중첩 아데노-관련 바이러스 벡터 시스템
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
GB201705765D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
CN110769850A (zh) 2017-05-15 2020-02-07 扬森疫苗与预防公司 稳定的含病毒组合物
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
CA3085492A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
SG11202005710YA (en) * 2017-12-19 2020-07-29 Janssen Sciences Ireland Unlimited Co Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
KR102234027B1 (ko) * 2018-05-09 2021-03-31 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드 및 이의 항바이러스 용도
KR20210074314A (ko) 2018-10-08 2021-06-21 얀센 파마슈티칼즈, 인코포레이티드 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘
CN114340663A (zh) * 2019-06-18 2022-04-12 爱尔兰詹森科学公司 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
US20220296703A1 (en) * 2019-06-18 2022-09-22 Janssen Sciences Ireland Unlimited Company Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
JP7635208B2 (ja) 2019-08-29 2025-02-25 ブイアイアール バイオテクノロジー インコーポレイテッド Ｂ型肝炎ウイルスワクチン
FI4037708T3 (fi) 2019-09-30 2024-10-31 Gilead Sciences Inc Hbv-rokotteita ja menetelmiä, hbv:n hoitamiseksi
JP2023505304A (ja) 2019-12-07 2023-02-08 アイエスエー ファーマシューティカルズ ビー．ヴイ． Ｂ型肝炎ウイルスに関連する疾患の治療
CN115461358A (zh) * 2020-07-17 2022-12-09 养生堂有限公司 一种细胞穿膜肽及其应用
CN114107377A (zh) * 2020-08-31 2022-03-01 复旦大学附属华山医院 一种乙肝病毒载体及其应用
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2025226656A1 (en) * 2024-04-23 2025-10-30 Modernatx, Inc. Hepatitis b virus mrna vaccines

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
FR2650838A1 (fr) 1989-08-09 1991-02-15 Transgene Sa Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
EP0491077A1 (en) 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
NZ270605A (en) 1991-08-26 1997-07-27 Cytel Corp Cytotoxic t lymphocyte inducing peptides (6-19 amino acids) and pharmaceutical compositions thereof
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU695261B2 (en) 1993-02-26 1998-08-13 Scripps Research Institute, The Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
WO1994029469A2 (en) * 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
EP0833668A4 (en) * 1995-06-20 2001-12-12 Gen Hospital Corp INHIBITATION OF THE HEPATITIS B VIRUS REPLICATION
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
US5981274A (en) * 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
ATE353956T1 (de) 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6596501B2 (en) * 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
JP3864610B2 (ja) 1998-05-21 2007-01-10 旭硝子株式会社 水分散型撥水撥油剤組成物およびその製造方法
SK7602001A3 (en) 1998-12-04 2002-03-05 Biogen Inc Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CA2356373A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
AU774437B2 (en) 1999-02-22 2004-06-24 Transgene S.A. Method for obtaining a purified viral preparation
ES2289426T3 (es) 1999-05-17 2008-02-01 Crucell Holland B.V. Adenovirus recombinante humano de serotipo 35.
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
AU2001252458A1 (en) * 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
RU2286172C2 (ru) * 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
EP1390398A2 (en) 2001-05-30 2004-02-25 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
JP4502642B2 (ja) * 2002-02-07 2010-07-14 メルボルン ヘルス ヌクレオシドアナログに対する感受性の変化を有するウイルス変種およびその使用
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
WO2004083418A1 (en) 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
CA2519207A1 (en) 2003-03-28 2004-11-11 Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
US7695960B2 (en) * 2003-06-05 2010-04-13 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
FR2855758B1 (fr) * 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
WO2004113370A1 (de) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh NEUE OBERFLÄCHENPROTEIN-(HBsAG-) VARIANTE DES HEPATITIS B VIRUS
AU2004260044B2 (en) 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
AU2004285983B2 (en) * 2003-10-21 2012-06-28 Alfred Health HBV variants detection and application
GB0328753D0 (en) 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
US8470591B2 (en) 2004-11-08 2013-06-25 Transgene S.A. Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal
EP1764369A1 (de) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
GB0522578D0 (en) 2005-11-04 2005-12-14 King S College London Ribozymal nucleic acid
JP5188400B2 (ja) * 2006-03-09 2013-04-24 トランスジーン エス．エー． Ｃ型肝炎ウイルスの非構造融合タンパク質
US20100129403A1 (en) 2006-06-20 2010-05-27 Transgene S.A. Recombinant viral vaccine
WO2008020656A1 (en) * 2006-08-14 2008-02-21 Postech Foundation A dna vaccine for curing chronic hepatitis b and a method of preparing same
US8337859B2 (en) * 2007-05-15 2012-12-25 Transgene S.A. Vectors for multiple gene expression
CN102015753A (zh) * 2008-01-25 2011-04-13 海德堡吕布莱希特-卡尔斯大学 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途
CA2770075C (en) * 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection

Also Published As

Publication number Publication date
JP2013501038A (ja) 2013-01-10
IL217926A (en) 2016-07-31
HK1223295A1 (zh) 2017-07-28
MX2012001592A (es) 2012-05-22
JP5897464B2 (ja) 2016-03-30
CN102573903B (zh) 2015-12-02
ZA201200899B (en) 2012-10-31
CN105535960B (zh) 2019-06-04
RU2555346C2 (ru) 2015-07-10
TW201106967A (en) 2011-03-01
CN102573903A (zh) 2012-07-11
WO2011015656A3 (en) 2011-03-31
KR20120052352A (ko) 2012-05-23
US20170072047A1 (en) 2017-03-16
JP2016074707A (ja) 2016-05-12
SG178254A1 (en) 2012-03-29
US9393299B2 (en) 2016-07-19
CA2770075C (en) 2021-08-24
CN105535960A (zh) 2016-05-04
JP6246778B2 (ja) 2017-12-13
EP2461826A2 (en) 2012-06-13
WO2011015656A2 (en) 2011-02-10
TWI555531B (zh) 2016-11-01
IL217926A0 (en) 2012-03-29
BR112012002628B1 (pt) 2021-09-08
CA2770075A1 (en) 2011-02-10
BR112012002628A2 (pt) 2016-11-08
AU2010280710A1 (en) 2012-03-01
RU2012107671A (ru) 2013-09-20
US20130011435A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
NZ598000A (en) Composition for treating hbv infection
EP2853531A3 (en) Antiviral compounds
WO2010075376A3 (en) Anti-viral compounds
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
ATE547103T1 (de) Hemmer des hepatitis-c-virus
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
WO2008033466A3 (en) Compositions and methods for treatment of viral diseases
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
WO2008021936A3 (en) Hepatitis c virus inhibitors
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
DK1951296T3 (da) Celleafledte virale vacciner med lave niveauer af restcelle-DNA
PH12013500708B1 (en) Anti-viral compounds
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
DK2261377T3 (da) Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner
EP2399575A3 (en) Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
EP2527445A3 (en) Treatment and prevention of influenza
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection
WO2008121487A3 (en) Live attenuated virus vaccines for la crosse virus and other bunyaviridae

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 AUG 2017 BY FREEHILLS PATENT ATTORNEYS

Effective date: 20140711

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2018 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20170713

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2019 BY ACUMASS

Effective date: 20180717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2020 BY ACUMASS

Effective date: 20190719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2021 BY ACUMASS

Effective date: 20200717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2022 BY ACUMASS

Effective date: 20210720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2023 BY ACUMASS

Effective date: 20220719

LAPS Patent lapsed